Healthy Clinical Trial
Official title:
A Phase 1, Randomized, Open-label, Crossover Study to Determine the Relative Bioavailability of Relacorilant Administered as 3×100-mg Softgel Capsules, 3×100 mg Hard Shell Capsules, and 6×50-mg Hard-shell Capsules in Healthy Adult Subjects
This is an open-label, randomized, 3 treatment, 3-period, 6-sequence, crossover study
conducted at a single study center to characterize the relative bioavailability of
relacorilant administered as 3×100-mg softgel capsules (Treatment A), 3×100 mg hard-shell
capsules (Treatment B), and 6×50-mg hard shell capsules (Treatment C/reference) in healthy,
fasted, adult subjects.
Eligible subjects will participate in 3 treatment periods. During each treatment period,
subjects will receive a single 300-mg relacorilant dose. An equal number of subjects will be
randomized to each of 6 sequences.
This is an open-label, randomized, 3 treatment, 3-period, 6-sequence, crossover study.
Eligible subjects will participate in 3 treatment periods. During each treatment period,
subjects will receive a single 300-mg relacorilant dose. An equal number of subjects will be
randomized to each of 6 sequences (i.e., ABC, BCA, CAB, BAC, ACB, and CBA):
(A) relacorilant single 300 mg dose (3×100-mg softgel capsules) following a minimum 10 hour
fast (Test 1) (B) relacorilant single 300 mg dose (3×100-mg hard-shell capsules) following a
minimum 10-hour fast (Test 2) (C) relacorilant single 300 mg dose (6×50-mg hard-shell
capsules) following a minimum 10 hour fast (Reference) Subjects will be admitted to the
Clinical Research Unit (CRU) on the morning of Day −1 of each period following an 8-hour fast
for baseline assessments and will remain confined until Day 3 of each period. After dosing in
Period 1 and Period 2, subjects will undergo minimum 14 day washouts between doses of study
drug. Subjects will then receive the next relacorilant dose in their randomized sequence in
Period 2 and Period 3, respectively. Subjects will attend an outpatient Follow-up Visit 14±2
days after the last dose of study drug in Period 3 (or Early Termination Visit).
Blood samples will be collected before dosing and at intervals up to 120 hours after
relacorilant dose in Periods 1, 2 and 3.
Safety and tolerability will be monitored using AEs, clinical laboratory evaluations, 12-lead
ECG recordings, vital signs, and physical examinations.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |